Nervous Disorder TRIZ Cases

Engineered CAR macrophages bind beta-amyloid and phagocytose plaques, offering targeted clearance with less reliance on systemic antibodies.

This case uses a low-affinity mu opioid receptor in targeted brain circuits to provide long-lasting relapse protection without daily dosing.

Linkage-specific antibodies detect linear polyubiquitin, reduce affinity for lysine-linked forms, and avoid monoubiquitin binding.

PEG or lipid sizing agents stabilize nanoalum particles, enabling filtration, terminal sterilization, and antigen delivery.

This case uses recombinant PRG4 to inhibit NGF sensitization, TrkA expression, and NGF/TrkA binding for acute and chronic pain relief.

A controlled nasal dispenser uses a membrane permeation enhancer to improve bioavailability and keep desmopressin levels predictable.

Specific acid salts improve crystallinity, humidity resistance, and industrial handling.

This case uses phosphorylated tau and related CSF biomarkers to improve Alzheimer’s staging and assess kinase inhibitor response.

This case uses PXRD-defined levodopa-tyrosine polymorphs to improve stability, solubility, bioavailability, and formulation flexibility.

This case combines beta-hydroxybutyrate with amino acids to improve ketone delivery while reducing excess sodium, magnesium, and potassium.

This case uses HCELL-expressing neural stem cells to target E-selectin on inflamed tissue, improving migration and colonization.

Combining macrocyclic crown ether structures into kinase inhibitors addresses insufficient enzyme inhibition and poor water solubility.

This case uses anti-IL-6 receptor antibodies to block cytokine signaling and improve abnormal sensorimotor gating.

EBV-specific CTLs focus immune activity on progressive MS treatment.

Basil extract targets amyloid and tau aggregation beyond temporary symptom relief.

IgG4 antibodies with S228P target S-(-)-nicotine, reducing plasma and brain levels for cessation and toxicity treatment.

This case removes O-demethylation and uses Suzuki, deprotection, and guanidine steps for scalable high-purity production.

This case uses dunnione and β-lapachone to reduce inflammatory cytokines and protect stem cells during anticancer treatment.

Timed Wnt, TGFβ, BMP, and FGF modulation generates enteric neural crest cells for Hirschsprung's disease models and drug screening.

This case uses 0.01–10000 mg/day dosing to reach 1–20 μM serum levels while balancing therapeutic effects and toxicity.

This case addresses over- or under-expression by pairing a PGK promoter and WPRE in an AAV vector for effective frataxin delivery.

Controlled oral CO formulations aim to slow neurodegeneration by preserving dopamine and reducing oxidative stress and inflammation.

This case combines PEA with hemp oil to enhance endocannabinoid activity and reduce pain while limiting synthetic-drug complexity.

This case uses biodegradable PLGA carriers to provide prolonged glatiramer acetate release, reducing injections while maintaining efficacy.

An antibody-tissue factor conjugate targets PLVAP on HCC tumor vessels, blocking blood flow to reduce tumor volume.

This case uses formula I HDAC inhibitors to cross the blood-brain barrier and address toxicity in aggressive brain cancers.

This case replaces unstable AC253 peptides with small molecules designed to cross the blood-brain barrier and block neurotoxicity.

Peripheral tissue antibody detection supports accurate ante-mortem Parkinson’s diagnosis.

Direct cortical infusion limits coverage in primate brains; thalamic CED uses thalamocortical pathways for broad distribution.

Pg OMVs deliver tRNA to modulate NRG1 expression across biological barriers.

This case uses AQP4 facilitators and α-2 agonists to enhance glymphatic influx, improving brain exposure and reducing variable distribution.

Epitope mapping helps select FAM19A5 antibodies that inhibit reactive gliosis and enhance neuronal survival and axon regrowth.

AAV or lentiviral delivery increases Pla2g2f expression to reduce neuroinflammation and support synapse maintenance, memory, and cognition.

An oil-in-water CBD emulsion uses nebulized nanoscale droplets to address poor solubility and respiratory irritation during inhalation.

This case examines scaffold and pharmacokinetic tuning to balance NLRP3 potency, blood-brain barrier penetration, and stability.

This case uses reverse transcriptase inhibitors upstream to suppress non-classical APP variants and reduce amyloid plaque formation.

Antibody-linked degrons recruit proteasomal or autophagic degradation to clear TDP-43 and huntingtin aggregates.

An IV crovalimab loading dose followed by lower subcutaneous doses maintains C5 inhibition for potential long-term nerve protection in GBS.

This case replaces injectable PCSK9 inhibitors with oral heterocyclic compounds to lower LDL-C and support patient compliance.

This case uses Trapidil alongside levodopa to reduce dyskinesia while preserving Parkinson’s motor-symptom treatment.

Tetrahydroquinoline compounds target HDAC6 selectively, addressing poor isoform selectivity and genotoxicity in HDAC inhibitors.

Esterified THC derivatives act as prodrugs, improving oral bioavailability and extending half-life after in vivo conversion.

This case examines purified CBD at controlled doses for canine situational anxiety, reducing stress-related cortisol without THC.

This case uses lipase-catalyzed transesterification to make physiologically compatible hydroxybutyrate esters with fewer by-products.

Selective GABAA γ1 PAMs target GABAergic signaling while limiting sedation.

An induction phase followed by lower-frequency oral esketamine dosing treats MDD while limiting peak levels and genotoxic risk.

This case combines carnivorous-plant extracts in a transdermal composition to inhibit viral replication and shorten disease duration.

Fusing IL13 with regulatory cytokines combines analgesic pathways in one molecule to extend relief and support neuroprotection.

PLGA-PEG-PLGA hydrogel releases funapide locally for 3–5 days, targeting Nav1.7 pain pathways while preserving motor function.

Shear and mechanical forces activate monocytes, enabling selective production of immuno-stimulatory or immuno-suppressive dendritic cells.